Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

FDA oncology roundup: drugs, imaging agents and diagnostics gain approval

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.

Latest news

Younger UK children to benefit from new dose of nasal spray allergy drug

The MHRA’s approval of a lower dose of EURneffy means more children will have a needle-free option to treat anaphylaxis.

ECRD 2026: Europe’s rare disease bottleneck is funding rather than science

Derisking assets to attract capital and rethinking funding models should be key priorities for Europe to retain its research pipeline.

Simcere and Stanford partner to develop IPF therapies

If the research is successful, Simcere may in-license the molecule and obtain all global rights to the product.

ECRD 2026: Navigating the rare disease diagnostic and drug development maze

While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.

FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment

The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients.

CDA data reveals trends on drug approvals and reimbursements in Canada

According to GlobalData POLI, the average time to reimburse in Canada for all branded drugs has steadily increased.